-IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the availability of the IDEXX Cancer Dx™ Pa...
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone...
Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this ye...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including...
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER...
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination ...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s in...
Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and...
In this BioPharma Boardroom interview, Steven Quay, Founder and CEO of Atossa Therapeutics, outlines the scientific rationale behind developing (Z)-endoxif...
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult pati...
The company also announced a strategic investment from Leonardo DiCaprio ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures an...
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule ...
225Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration...
© 2026 Biopharma Boardroom. All Rights Reserved.
